Goodwin, Davis Polk Steer Biotech Firm's Upsized $175M IPO
Gene-editing focused biotechnology firm Prime Medicine Inc. began trading Thursday after pricing an upsized $175 million initial public offering, steered by Goodwin Procter LLP and underwriters counsel Davis Polk & Wardwell...To view the full article, register now.
Already a subscriber? Click here to view full article